CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors

This study is testing CAR-T cell therapy — a form of immune cell therapy engineered to target a protein called CEA — in patients with advanced solid tumors such as colorectal, esophageal, gastric, or pancreatic cancer. **You may be eligible if:** - You are 18 or older - You have an advanced, metastatic, or recurrent solid tumor (mainly colorectal, esophageal, gastric, or pancreatic cancer) - Your tumor tests positive for the CEA protein and your blood CEA level is above 10 - You have already tried at least two prior treatment regimens and they have not worked - You are in reasonably good health (ECOG 0–2) and your organs are functioning adequately **You may NOT be eligible if:** - You have a serious mental disorder - Your heart ejection fraction is below 50% - Your kidney, liver, or blood counts do not meet the required levels - You have poor blood oxygen levels Talk to your doctor to see if this trial is right for you.